MedTrace Logo

Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

NCT02446704 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2022-02-07

No results posted yet for this study

Summary

This research study is evaluating the combination of olaparib and temozolomide as a possible treatment for Small Cell Lung Cancer.

Conditions

Interventions

DRUG

Olaparib

DRUG

Temozolomide

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Zofia Piotrowska

    lead OTHER

Principal Investigators

  • Anna Farago, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-13
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02446704 on ClinicalTrials.gov